<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050361</url>
  </required_header>
  <id_info>
    <org_study_id>321-09-FB</org_study_id>
    <nct_id>NCT01050361</nct_id>
  </id_info>
  <brief_title>Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery</brief_title>
  <acronym>EGHEM</acronym>
  <official_title>Echocardiography-Guided Hemodynamic Management Strategy for Patients Requiring Perioperative Care for Non-Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The growing population of University of Nebraska Medical Center patients with heart failure
      combined with the increasing number of surgical procedures performed each year supports the
      need for a critical analysis of how to most appropriately manage these patients during the
      perioperative period, especially for non-cardiac surgery. Echo-guided hemodynamic management
      (EGHEM) is the use of echocardiography data to normalize and/or optimize in real-time,
      cardiac output and ventricular filling pressures in the perioperative period for non-cardiac
      surgical cases. The purpose of this study is to test the hypothesis that EGHEM compared to
      standard management practices will result in a reduced length of hospital stay in the
      noncardiac surgery population. The primary goal of health care providers for patients
      requiring anesthetic care, perioperative care, or critical care is ensuring the adequacy of
      the patient's circulatory function by optimizing cardiac output and ventricular filling
      pressure. Currently, the use of the ECG monitor and systemic blood pressure are the standard
      of care for assessing circulatory function. However, those data cannot provide accurate
      information on cardiac output and ventricular filling pressure for patients with
      cardiovascular risk factors and/or comorbidities. As a result, managing the hemodynamic
      parameters of these patients, as well as their intravenous fluid needs and resuscitation
      strategy, we hypothesize that using traditional approaches may lead to significant volume
      overload and post-operative cardiovascular complications and morbidity. In this study we
      propose an EGHEM strategy that incorporates standard echocardiography generated data points
      in addition to the systemic blood pressure and ECG signal to assess, manage, modify and
      optimize patient cardiac preload, afterload, heart rate and contractility in the
      perioperative period. Based on our initial observations and preliminary data using the EGHEM
      approach, we hypothesize that we can demonstrate a significant decrease in hospital length of
      stay and an overall decrease in perioperative morbidity at 30 days in the non-cardiac surgery
      population using EGHEM compared to standard practices. In this proposal we have designed a
      single center, prospective, randomized clinical trial to test our hypothesis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Step 1: Patient selection

      The first step in the EGHEM/EGAM process is appropriate patient selection. Patients who have
      any of the following cardiovascular risk factors and/or comorbidities and are scheduled for a
      non-cardiac surgery are candidates for EGHEM/EGAM:

        1. Urology/gynecology/General surgical patient

        2. Non-cardiac surgical population

        3. age 65 years or older, OR 19 years or older and one of the following risk factors:

             1. Hypertension (HTN)

             2. Diabetes

             3. Obesity (body mass index [BMI] &gt;35)

             4. Renal insufficiency

             5. Tobacco usage

             6. Hypercholesterolemia

             7. Sleep apnea/heavy snoring at night

             8. Clinical diagnosis of CHF as defined by:

                  -  Dyspnea on exertion

                  -  Paroxysmal nocturnal dyspnea

                  -  Orthopnea

                  -  Elevated jugular venous pressure

                  -  Pulmonary rales

                  -  Third heart sound

                  -  Cardiomegaly or pulmonary edema on chest x-ray

                  -  Peripheral edema

                  -  Hepatomegaly

                  -  Pleural effusion

             9. Palpitations/irregular heart beats

            10. Chest pain at rest and or exercise

            11. Murmur on examination

            12. Known coronary artery disease (CAD)/stents/coronary artery bypass graft (CABG)

            13. Known valvular disease

            14. Known stroke or transient ischemic attacks (TIA) Standard Medical Care Step 2:
                Pre-op assessment

      Step 2 in the EGAM process involves a bedside, transthoracic echocardiography (TTE) pre-op
      assessment. The pre-op TTE should be performed by one of the co-investigators, and take less
      than 10 minutes to complete. The information acquired by TTE during the pre-op assessment
      should include the following five evaluations, in order of importance:

        1. Cardiac output on the left side of the heart using spectral Doppler measurements;

             1. Left ventricular outflow tract (LVOT) velocity time integral (VTI)

             2. Heart rate

        2. Filling pressures on the left side of the heart using spectral Doppler measurements;

             1. The pulmonary venous flow pattern defined as co-dominant, systolic dominant or
                diastolic dominant

             2. The mitral inflow pattern defined as normal, impaired relaxation, pseudonormal or
                restrictive

             3. The E/e' ratio of velocities

        3. Mitral valve structure and function;

        4. Aortic valve structure and function; and

        5. Biventricular contractility.

      These evaluations are performed using the following TTE views:

      A. Parasternal (PS) window: With the patient in the left lateral decubitus position, the TTE
      probe is placed on the 3rd left intercostal space next to the sternum; the light on the probe
      should be directed toward the patient's right shoulder. The 2-dimensional image of the long
      axis (LAX) should be acquired first. In this view, the following are evaluated:

        -  Color Doppler on aortic valve (AV) and mitral valve (MV)

        -  E-point septal separation (EPSS) To evaluate the PS short axis (SAX), the probe should
           be rotated clockwise 60 degrees. The 2-dimensional view should be obtained at the
           mid-papillary level.

      B. Apical window: With the patient in the same left, lateral, decubitus position, the probe
      is placed between the 5th and 6th intercostal space on the left side, close to the nipple
      line. The light on the probe should be directed toward the floor or the bed for the 4-chamber
      view. The following assessments should be performed in the 4-chamber view:

        -  Two-dimensional image;

        -  Pulsed-wave (PW) Doppler in the right upper pulmonary vein;

        -  PW Doppler at the tip of the MV;

        -  PW Doppler on the MV annulus for tissue Doppler;

        -  Color Doppler on the tricuspid valve (TV) and MV if necessary based on the PS LAX
           window.

      For the apical LAX, the probe should be rotated counterclockwise so that the light is
      directed toward the patient's right shoulder. In the LAX view, velocity time integrals (VTIs)
      using PW in the left ventricular outflow track (LVOT) and continuous wave (CW) at the level
      of the AV should be acquired.

      C. Subcostal window: With the patient supine, the TTE probe is placed under the right costal
      ridge and directed toward the heart. The light should be directed toward the sonographer
      (toward the patient's left) to assess the 4-chamber view.

      For the subcostal inferior vena cava (IVC) view, the probe should be slightly rotated
      counterclockwise until the IVC can be assessed.

      Standard Medical Care Step 3: Management strategies Step 3 in the EGHEM/EGAM process is to
      define patient management strategies based on the pre-op TTE assessment. The main goals of
      patient management are to maintain normal cardiac output and filling pressure. Primary and
      secondary findings and the associated EGAM strategies to achieve these goals are outlined in
      Table 1 and Table 2, respectively.

      Table 1: Primary findings and associated management strategy to maintain normal cardiac
      output and filling pressure.

      Echo-Generated Findings EGHEM/EGAM Strategy Cardiac output status Filling pressure status
      Normal High Preload reduction Low Normal Afterload reduction Low High Afterload and preload
      reduction High High Preload reduction High Normal or low Increase preload

      Table 2: Secondary findings and associated management strategy to optimize patient
      management.

      Echo-Generated Finding EGHEM/EGAM Strategy Filling Pressure Other High Aortic stenosis
      Preload reduction Normal Aortic stenosis Safe for afterload reduction

        -  Mitral regurgitation Afterload reduction

        -  Low contractility Inotropic support

        -  Suspected or confirmed CAD Maintain heart rate in the 50 - 60 bpm range RV volume
           overload Preload reduction RV pressure overload Pulmonary afterload reduction Standard
           Medical Care Step 4: Ongoing intra-operative assessment Based on the appropriate EGAM
           strategy defined in Step 3, either TEE or TTE should be used during the surgical
           procedure for the ongoing patient assessment every 15 to 20 minutes. The PI or Secondary
           Investigator will determine whether a TEE or TTE should be conducted intra-operatively.
           The results of these tests will be used for research purposes. During surgery: fluid
           administration, afterload adjustments, and supported contractility can be implemented to
           optimize patient management. It is difficult to assess cardiac output with the current
           standard medical care without invasive monitoring. There is minimal risk if the
           physician gets distracted by the echocardiogram or the algorithm of the study however it
           is unlikely this tool would be a distraction to the physician as it is monitoring the
           patient.

      The randomization is very thought through due to the fact that any Urology/Gynecology/General
      surgical patient will be consented for the study so there for no specific demographics are
      being recruited other than what is in the inclusion criteria. Currently for the UNMC
      Urology/Gynecology surgical patients the distribution lies such that 47 percent are men and
      53 percent are women.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To use standard cardiac ultrasound-generated data points in addition to systemic blood pressure and ECG signal to assess, manage, modify, and optimize the patient cardiac preload, afterload, heart rate and contractility in the perioperative period.</measure>
    <time_frame>3 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To reduce perioperative morbidity and mortality associated with congestive heart failure for non-cardiac surgeries.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate and support the conclusion that echocardiography is a superior technology for identifying these changes and managing the unique cardiovascular challenges of the UNMC patient population.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Cardiovascular Risk Factors</condition>
  <arm_group>
    <arm_group_label>EGHEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention group will be called EGHEM - Echo Guided HEmodyanmic Management - and will receive their intraoperative maintenance fluid and possible drug therapy (furosemide) based on their hourly intraoperative LVDD grade.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SHEM</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will be
called SHEM - Standard HEmodynamic Management - and will NOT receive the study intervention, but will receive standard anesthesia and hemodynamic management based on current standards within the institution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)</intervention_name>
    <description>Duration lasts the entire operation.</description>
    <arm_group_label>EGHEM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 65 years

          2. Hypertension (HTN)

          3. Diabetes

          4. Obesity (body mass index [BMI] &gt;35)

          5. Renal insufficiency

          6. Tobacco usage

          7. Hypercholesterolemia

          8. Sleep apnea/heavy snoring at night

          9. Clinical diagnosis of CHF as defined by:

               1. Dyspnea on exertion

               2. Paroxysmal nocturnal dyspnea

               3. Orthopnea

               4. Elevated jugular venous pressure

               5. Pulmonary rales

               6. Third heart sound

               7. Cardiomegaly or pulmonary edema on chest x-ray

               8. Peripheral edema

               9. Hepatomegaly

              10. Pleural effusion

         10. Palpitations/irregular heart beats

         11. Chest pain at rest and or exercise

         12. Murmur on examination

         13. Known coronary artery disease (CAD)/stents/coronary artery bypass graft (CABG)

         14. Known valvular disease

         15. Known stroke or transient ischemic attacks (TIA)

        Exclusion Criteria:

          1. Patients expected to say in the hospital for less than 24 hours.

          2. Inability of undergo TEE and TTE

          3. Clinical evidence or suspicion of elevated intracranial pressure.

          4. Preoperative shock or systemic sepsis

          5. Emergency Operation

          6. ASA Class V

          7. Inability of give informed consent

          8. Participation in another clinical trial

          9. Prisoner
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tara R Brakke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2010</study_first_posted>
  <last_update_submitted>May 16, 2016</last_update_submitted>
  <last_update_submitted_qc>May 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Tara Brakke MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>To reduce perioperative morbidity and mortality associated with congestive heart failure for non-cardiac surgeries</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

